GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (FRA:354) » Definitions » Price-to-Operating-Cash-Flow

Collegium Pharmaceutical (FRA:354) Price-to-Operating-Cash-Flow : 5.34 (As of May. 22, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Collegium Pharmaceutical Price-to-Operating-Cash-Flow?

As of today (2025-05-22), Collegium Pharmaceutical's share price is €26.20. Collegium Pharmaceutical's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €4.90. Hence, Collegium Pharmaceutical's Price-to-Operating-Cash-Flow Ratio for today is 5.34.

The historical rank and industry rank for Collegium Pharmaceutical's Price-to-Operating-Cash-Flow or its related term are showing as below:

FRA:354' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.8   Med: 7.07   Max: 30.81
Current: 5.51

During the past 12 years, Collegium Pharmaceutical's highest Price-to-Operating-Cash-Flow Ratio was 30.81. The lowest was 2.80. And the median was 7.07.

FRA:354's Price-to-Operating-Cash-Flow is ranked better than
89.56% of 699 companies
in the Drug Manufacturers industry
Industry Median: 17.11 vs FRA:354: 5.51

Collegium Pharmaceutical's Cash Flow from Operations per share for the three months ended in Mar. 2025 was €1.56. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €4.90.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Collegium Pharmaceutical was -22.90% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 26.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 41.40% per year.

During the past 12 years, Collegium Pharmaceutical's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.20% per year. The lowest was -21.10% per year. And the median was 14.45% per year.


Collegium Pharmaceutical Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Collegium Pharmaceutical's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Price-to-Operating-Cash-Flow Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.49 7.40 6.32 4.68 5.65

Collegium Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.73 5.27 9.36 5.65 5.72

Competitive Comparison of Collegium Pharmaceutical's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Price-to-Operating-Cash-Flow falls into.


;
;

Collegium Pharmaceutical Price-to-Operating-Cash-Flow Calculation

Collegium Pharmaceutical's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=26.20/4.904
=5.34

Collegium Pharmaceutical's Share Price of today is €26.20.
Collegium Pharmaceutical's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.90.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Collegium Pharmaceutical Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Collegium Pharmaceutical Headlines

No Headlines